Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Sun Pharma bets on new...

    Sun Pharma bets on new products to boost US skincare products growth

    Written by savita thakur thakur Published On 2016-06-24T14:36:16+05:30  |  Updated On 24 Jun 2016 2:36 PM IST
    Sun Pharma bets on new products to boost US skincare products growth

    Mumbai : India's largest drugmaker Sun Pharmaceutical Industries is banking on the launch of newer and more complex products to offset rising competition in its lucrative U.S. dermatology business, its U.S. chief said.


    The world's fifth-largest maker of generic drugs was the first among its Indian peers to enter the roughly $5 billion U.S. dermatology space by acquiring a controlling stake in Israel's Taro Pharmaceutical Industries Ltd in 2010.


    That marked a major effort by Sun to scale up its niche and specialty drugs pipeline, as the market for plain vanilla generics most large Indian drugmakers' bread and butter until then started to get increasingly crowded with smaller players.


    But as competition has heated up in the last few years, many companies have also sought niche markets, and dermatology has attracted quite a few. India's Lupin bought U.S. firm Gavis to expand in dermatology, and Glenmark Pharmaceuticals is scaling up its pipeline too.


    Mid sized drugmakers such as Torrent Pharmaceuticals and Alembic Pharmaceuticals are working on skin treatments, and many small U.S. firms are increasingly challenging Sun's share in the market, analysts say.


    Kal Sundaram, who heads Sun's operations in the United States, its largest market, said the company would lose some share in dermatology in the short term, but was confident of its pipeline of new products driving growth.


    "While the competitive intensity will increase, it is not going to be like atorvastatin (Lipitor), where you have 10 or 15 manufacturers," Sundaram told Reuters. "(In dermatology), maybe from three (manufacturers) it would go to about five."


    Sun has high hopes for tildrakizumab, an experimental psoriasis drug that recently completed late-stage trials, full results of which are due out soon.


    Most dermatology drugs require clinical studies for approval, which Kal said cost between $7 million and $10 million, on average, "and there is no guarantee if they will be successful," thus limiting competition.


    Nimish Mehta, founder and director of Research Delta Advisors, said he expects Taro's sales to rise 18 percent this fiscal year based on approvals for new dermatology products.


    Price hikes have largely helped Sun grow its dermatology business over the years, but they are harder to make after a recent wave of consolidation between U.S. drug distributors.


    Sundaram said the company expects pressure on prices in the short term, but it is betting on expanding volumes.

    AlembicGavis PharmaGlenmark PharmaKal SundaramLupinNimish Mehtaprice hikeskincareskincare products growthSun PharmaTaro PharmaceuticalTorrent
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok